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Abstract: Cardiovascular disease (CVD) is the leading cause of death among men and women 
worldwide. In CVD, hypertension and dyslipidemia commonly coexist and are managed through 
coadministration of amlodipine and atorvastatin, respectively. The case for fixed-dose combi-
nation (FDC) oral dosage forms and orally disintegrating tablet (ODT) technology to enhance 
outcomes and compliance is strong. This work follows the development and characterization 
of single and FDC ODTs containing amlodipine and atorvastatin, followed by bioequivalence 
comparison between these single and FDC formulations, using in vitro dissolution and Caco-2 
apparent permeability (P
app
) and in silico physiologically based pharmacokinetic modeling 
approaches. ODTs containing amlodipine (5 mg) and atorvastatin (10 mg) either alone or in 
combination rapidly disintegrated (30 s) while displaying a radial crushing strength in excess 
of 100 N and friability 1%. In vitro dissolution test was performed in fasted and fed-state 
simulated intestinal fluid (FeSSIF) and analyzed using high-performance liquid chromatography. 
Dissolution profiles for single and FDC ODTs were compared using US FDA recommended 
difference (f
1
) and similarity (f
2
) factor testing for bioequivalence. In all cases, there was no 
difference in active pharmaceutical ingredient dissolution between single or FDC ODTs, with 
the exception of amlodipine in FeSSIF. Pharmacokinetic clinical trial simulations were con-
ducted using Simcyp (Version 14), incorporating P
app
 and dissolution data. Simulated clinical 
trials in healthy volunteers showed no difference in bioavailability based on pharmacokinetic 
parameters between single and combination doses with either active pharmaceutical ingredient. 
An increase in C
max
 and AUC for atorvastatin in fed subjects was attributed to extended transit 
along the gut lumen and reduced atorvastatin metabolism due to lower CYP3A4 expression 
at more distal small intestine absorption sites. The results demonstrated bioequivalence of an 
FDC ODT for amlodipine and atorvastatin, while highlighting several limitations of f
1
 and 
f
2
 bioequivalence testing and strengths of mechanistic pharmacokinetic modeling for oral 
drug absorption.
Keywords: orally disintegrating tablet, fixed-dose combination, cardiovascular disease, 
physiologically based pharmacokinetic modeling, bioavailability, bioequivalence
Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide, claiming an 
estimated 17.3 million lives per year, a death toll that is expected to rise to in excess 
of 23.6 million by 2030. Deaths from CVD accounted for 30% of global deaths in 
2008, more than all forms of cancer combined.1
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CVD is multifactorial, with risk factors such as hyper-
tension, dyslipidemia, diabetes mellitus, smoking, and 
obesity frequently coexisting.2 One of the most common 
risk factor combinations is dyslipidemia (elevated levels 
of low-density lipoprotein [LDL] and triglyceride and low 
levels of high-density lipoprotein [HDL]) and hypertension.3 
Studies have demonstrated the link between hypertension 
and metabolically associated risk factors;4 in a retrospective 
study of US veterans, for example, the prevalence of CVD 
was commonly double in patients exhibiting both hyperten-
sion and dyslipidemia when compared to those with either 
condition alone.5 In the UK, a 2004 analysis of the medical 
records of over 600,000 patients revealed a 14.7% incidence 
of subjects with both hypertension and dyslipidemia.6
Amlodipine (Biopharmaceutics Classification System 
[BCS] class I)7 is a third-generation dihydropyridine calcium 
channel blocker, a class of drug that works to lower blood 
pressure in hypertensive patients through relaxation of vas-
cular smooth muscle and vessel dilation.8 It acts by inhibit-
ing “slow” influx of extracellular calcium into cardiac and 
vascular cells via blockade of voltage-gated L-type calcium 
channels.9,10 Amlodipine’s slow onset of action is responsible 
for a low incidence of reflex tachycardia and other vasodilator 
side effects when compared to other dihydropyridines, while 
its slow elimination and resultant long duration of action 
grants the convenience of a once-daily dosage regime.11
Atorvastatin (BCS class II),12 a 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitor, is 
used extensively in the treatment of dyslipidemia.13 HMG-
CoA reductase catalyzes the conversion of HMG-CoA to 
mevalonate. Its inhibition reduces hepatocyte cholesterol 
levels, leading to upregulation of LDL cholesterol (LDL-C) 
cell surface receptors and resulting in increased clearance 
of LDL-C from plasma.14,15 Atorvastatin reportedly reduces 
LDL-C in hypercholesterolemic patients by 41%–61%16 and 
reduces total cholesterol and plasma triglycerides alongside 
a modest increase in HDL cholesterol (HDL-C) levels.17
Despite the substantial risk of patients suffering from both 
dyslipidemia and hypertension, successful treatment falls 
short.18 A major reason for this is poor patient compliance, for 
reasons including cost, treatment regime complexity, extent 
of concomitant treatment, and side effects.16,19,20 Several 
clinical studies have examined the efficacy and safety of 
amlodipine and atorvastatin combination therapy in patients 
with concurrent hypertension and dyslipidemia. Combination 
therapy has been shown to achieve blood pressure and LDL 
goals.21,22 The RESPOND study, which compared combina-
tion therapy with amlodipine or atorvastatin, alone showed no 
difference in efficacy,23 whereas the AVALON study reported 
an increased efficacy with combination therapy over either 
drug alone.24 Furthermore, when amlodipine and atorvastatin 
are administered in a fixed-dose combination (FDC), there 
is no significant difference in bioavailability (based on t
max
, 
C
max
, and AUC) compared to coadministered matching doses 
of individual amlodipine and atorvastatin tablets.25
An amlodipine and atorvastatin FDC is, therefore, an 
attractive prospect with the view of improving patient com-
pliance. In addition to demonstrating bioequivalence in vivo, 
in combination, both amlodipine and atorvastatin allow for 
once-daily dosing and have no issues with tolerability.16 
Indeed, an amlodipine and atorvastatin FDC (Caduet®; Pfizer, 
New York, NY, USA) was approved in 2004 as the first FDC 
to treat two CVD categories.26
Orally disintegrating tablets (ODTs) are an appealing 
solid dosage form that rapidly disintegrates upon contact 
with saliva, typically within 30 s, eliminating the need for 
swallowing.27 This is pertinent to patients with dysphagia, a 
difficulty in swallowing, a condition estimated to affect as 
much as 50% of the population,28 while a recent patient survey 
across 11 general practices reported an incidence of 37.4%.29 
Dysphagia is particularly prevalent in pediatric and geriatric 
populations, institutionalized and psychiatric patients, those 
suffering from nausea and vomiting, and individuals with 
lack of access to water.30,31 Other benefits of ODTs include 
accurate dosing, rapid onset of action, good mouth feel, new 
business opportunities, and low production costs.30
In the application for and approval of generic medicinal 
formulations, the demonstration of bioequivalence is funda-
mental. Bioequivalence is based on the assumption that when 
two medicinal products display equivalent bioavailability, 
they will have the same therapeutic effect and thus provide 
comparable in vivo performance, in terms of both efficacy and 
safety.32 A product is deemed bioequivalent when there is no 
significant difference in the rate and extent to which the active 
pharmaceutical ingredient (API) becomes available within 
the systemic circulation, when compared with a reference 
drug product.33 Bioequivalence testing may also be applied 
in other situations, including the assessment of FDCs.32 For 
immediate release formulations, in vitro dissolution testing 
can be used to waive bioequivalence requirements, with the 
US FDA recommending a dissolution profile comparison 
approach, comprising a difference factor (f
1
) and similarity 
factor (f
2
).33,34 For rapidly dissolving medicinal products 
displaying greater than 85% dissolution within 15 min, com-
parison testing is not necessary, under the condition that the 
API falls within BCS class I or III (although class III carries 
stricter requirements).32 The potential for biowaiver extension 
to BCS class II compounds is an area of much interest.35–37
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Over the past 20 years, pharmacokinetic modeling and 
simulation have become an established tool to improve 
efficiency and reduce cost during drug development and 
ADME (absorption, distribution, metabolism and excretion) 
assessment. Physiologically based pharmacokinetic (PBPK) 
modeling describes the tissues and organs in the body as 
defined compartments, which are assigned physiologi-
cally relevant parameters and connected via physiological 
perfusion rates.38 PBPK models are used to estimate the 
pharmacokinetic profile of a drug at a target tissue or organ 
by taking into account ADME considerations throughout all 
compartments.39,40 As such, PBPK models have become a 
powerful tool for prediction of oral drug absorption (to the 
systemic circulation) through integration of common in vitro 
drug-specific information, such as physicochemical and cell-
based permeability data, with systems-based (physiological, 
anatomical, and biochemical) data.41,42 PBPK modeling is 
often exploited for prediction of oral drug absorption, con-
cerning the effect of formulation changes43,44 or FDCs,45 for 
example, and there is a significant effort to employ PBPK 
modeling to determine bioequivalence.46–48
The potential to enhance therapy for patients suffering 
both dyslipidemia and hypertension with an orally disinte-
grating FDC for amlodipine and atorvastatin is substantial. 
Since no change in bioavailability for amlodipine and 
atorvastatin from FDCs has been reported, it is expected 
that FDC ODTs, given their immediate disintegration and 
therefore rapid drug release, should show similar findings. 
Furthermore, the ability of ODTs to increase patient compli-
ance due to their convenience as a dosage form would likely 
enhance CVD therapy. In this work, an FDC ODT for amlo-
dipine and atorvastatin was developed and characterized. 
Single-dose and fixed-dose drug dissolution from ODTs 
were tested in biorelevant media, while drug permeability 
across Caco-2 cell monolayers was measured for prediction 
of in vivo pharmacokinetics and bioequivalence of FDCs 
compared to single-dose formulations, through PBPK com-
putational modeling.
Materials and methods
Materials
Amlodipine besylate (herein referred to as amlodipine) was 
purchased from Molekula Ltd (Gillingham, UK) and atorvas-
tatin calcium (herein referred to as atorvastatin) from Chemical 
Point (Oberhaching, Germany). Pearlitol® Flash (mannitol-
starch copolymer) was obtained from Roquette Pharma (Les-
trem, France), and Avicel PH-102 micro-crystalline cellulose 
(MCC) and sodium stearyl fumarate (SSF) were purchased 
from FMC BioPolymer (Philadelphia, PA, USA).
Biorelevant fasted-state simulated intestinal fluid 
(FaSSIF)/fed-state simulated intestinal fluid (FeSSIF)/ 
fasted state simulated gastric fluid (FaSSGF) Instant Powder 
was purchased online from biorelevant.com (UK). Sodium 
hydroxide, sodium chloride, sodium phosphate, and glacial 
acetic acid for biorelevant media were obtained from Sigma-
Aldrich (Gillingham, UK). Acetonitrile (ACN) and methanol 
(high-performance liquid chromatography [HPLC]-grade) 
were obtained from Fisher Scientific (Loughborough, UK).
For cell culture media, Dulbecco’s Modified Eagle’s 
Medium (DMEM) was purchased from Lonza (Wokingham, 
UK). Fetal bovine serum (FBS), gentamicin (10 mg/mL), 
Fungizone (amphotericin B 250 μg/mL), Hanks’ balanced salt 
solution (HBSS), and penicillin/streptomycin (10,000 U/mL) 
were all purchased from Gibco (Thermo Fischer Scientific). 
Trypsin-Ethylenediaminetetraacetic acid solution (0.25%) was 
procured from Sigma-Aldrich (Gillingham, UK). Caco-2 cells 
were purchased from the European Collection of Authenti-
cated Cell Cultures (ECACC) via Public Health England.
hPlc
HPLC was performed on an Agilent 1260 series (Agilent 
Technologies, Santa Clara, CA, USA), comprising a quar-
ternary pump, Infinity variable wavelength detector, and 
autosampler. Analysis was conducted on a reversed-phase 
Gemini C18, 150×4.6 mm, 110 Å, 5 μm column (Phenom-
enex, Macclesfield, UK). Protocols were developed, cali-
brated, and validated for both amlodipine and atorvastatin 
alone and in combination.
Separations were achieved using 0.1% (v/v) TFA and ACN 
at different ratios as the mobile phase. Amlodipine separation 
was performed with an isocratic mobile phase of TFA:ACN 
(57.5:42.5 v/v), a flow rate of 1 mL/min, and a wavelength 
of 360 nm. Atorvastatin separation was achieved using an 
isocratic mobile phase of TFA:ACN (50:50 v/v), a flow rate 
of 1.2 mL/min, and a wavelength of 246 nm. Separation of 
amlodipine and atorvastatin in combination required a mobile 
phase of TFA:ACN delivered at a gradient (65:35 to 35:65 v/v), 
with a flow rate of 1.5 mL/min, and a wavelength of 240 nm. 
An injection volume of 20 μL was used throughout.
HPLC method validation involved assessment of pre-
cision through intra-day variation, accuracy by multilevel 
recovery studies, instrument precision, linearity, and limit 
of detection and quantification (LOD and LOQ). Stock solu-
tions (1 mg/mL) of each drug were prepared (using ACN 
and methanol as solvents for amlodipine and atorvastatin, 
respectively) from which dilutions and subsequently 
twofold serial dilutions were prepared to form a calibra-
tion curve.
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Tablet production
Direct compression of tablets (500 mg) was performed on an 
Atlas T8 automatic press (SPECAC, Orpington, UK), using 
a 13 mm round, flat-faced die. Tablets were produced under 
ambient conditions.
Friability
Tablet friability was determined on 6 tablets using an F2 
friability tester (Sotax, Aesch, Switzerland). Tablets were 
placed inside a drum and rotated at 25 rpm for a total of 100 
revolutions. Dust was removed pre- and posttesting to remove 
excess powder that would contribute to tablet mass. Friability 
was calculated and expressed as percent tablet weight loss 
from initial tablet weight.
Tablet hardness
A Tablet Hardness Tester TBF1000 (Copley Scientific, 
Nottingham, UK) was used to measure the radial crushing 
strength (hardness) of tablets in triplicate.
Dissolution testing
API dissolution from ODTs in 900 mL biorelevant media was 
tested in both FaSSIF and FeSSIF at pH 6.5 and 5, respec-
tively, and maintained at 37°C. An ERWEKA DT 600 USP 
2 paddle apparatus (Heusenstamm, Germany) was used at 
a paddle speed of 50 rpm.27 A total of 5 mL of sample was 
taken over 2 h, replacing with 5 mL fresh media to simulate 
sink conditions. API dissolution was measured using HPLC 
and corrected for percent dose dissolved.
cell culture
Prior to seeding, cells were trypsinized (2.5 mL) from 75 cm2 
cell culture flasks (Corning Inc., Corning, NY, USA) on 
which they had been grown (80% confluence), after wash-
ing with HBSS. Caco-2 cells (passage 54–58) were seeded 
onto Transwell (Corning) semi-permeable membrane sup-
ports (12 well, 1.12 cm2, 0.4 μm pore size) at a density of 
8×104 cells/cm2. Cells were maintained in DMEM containing 
l-glutamine (4 mM) and glucose (4.5 mg/mL) supplemented 
with (v/v) 10% FBS, 1% penicillin/streptomycin, 1% non-
essential amino acids, amphotericin B (0.5 μg/mL), and 
gentamicin (20 μg/mL). Media were changed every 2–3 days 
and transwells cultured at 37°C, 5% CO
2
 for 21 days, after 
which transport studies were performed.
Transepithelial electrical resistance 
(Teer) measurements
TEER value measurements were performed to monitor 
monolayer integrity using an EVOM meter (World Precision 
Instruments, Sarasota, FL, USA). TEER values are expressed 
using the following equation:
 
TEER cm Resistance Blank resistance
Membrane surface 
( )Ω⋅ − ×2 =
area (cm )2  
caco-2 transport studies
Caco-2 monolayers were used for transport studies between 
21 and 24 days post-seeding. Drug absorption through Caco-2 
monolayers was measured for amlodipine and atorvastatin 
alone and in combination in both the apical to basolateral 
(A–B) and basolateral to apical (B–A) directions (n=3). 
Transport studies were carried out in DMEM (37°C) contain-
ing 10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) (pH 7.4), with 0.5 and 1.5 mL in the A and B compart-
ments, respectively. Samples of 100 μL were removed from 
the A side and 200 μL from the B side at time points over 
2 h, replacing with fresh prewarmed media (37°C) to mimic 
sink conditions. For mass balance, samples were taken from 
the donor compartments at t =0 and t =120 min.
Amlodipine was administered at a concentration equiva-
lent to 20 μg/mL (representing a dose of 5 mg in 250 mL) 
and atorvastatin at a concentration equivalent to 40 μg/mL 
(representing a dose of 10 mg in 250 mL). Cultures were 
maintained at 37°C and 5% CO
2
 throughout the experiment. 
Samples were analyzed by HPLC, and apparent permeability 
(P
app
) values were calculated using the following equation:
 
P
dQ dt
C Aapp
0
=
×
( / )
( )
 
where dQ/dt is the mass transfer rate of the compound from 
the donor to the receiver compartment, C
0
 is the initial con-
centration in the donor chamber, and A is the monolayer 
surface area (cm2).
clinical trials simulation
The population-based clinical trials simulator Simcyp (V14) 
(Certara, Princeton, NJ, USA) was used to simulate the plasma 
concentration of atorvastatin and amlodipine from single API 
and FDC formulations. Default parameter values for creating 
a North European Caucasian population were selected.49
compound data
Physicochemical information for each API was collated 
from the literature and used to develop compound files 
(Table 1). Simulations were performed using a minimal-
PBPK model. Where uncertainty arose regarding the precise 
value of compound data parameters, parameter estimation 
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was conducted using the Parameter Estimation Module to 
optimize parameter values. The ADAM (advanced dissolu-
tion, absorption and metabolism) model43 was assumed for all 
simulations and the dissolution profile for each formulation 
(single and FDC) in FaSSIF and FeSSIF was utilized.
clinical studies
The optimization and validation of the PBPK model were 
conducted using clinical study results reported in healthy 
adult subjects. For atorvastatin, study 1 included a 20 mg 
tablet dosed to 36 healthy volunteers (18–45 years old),50 
study 2 included a 20 mg tablet dosed to 24 healthy 
subjects,51 study 3 included an 80 mg capsule dosed to 36 
healthy subjects (20–50 years old),52 and study 4 included a 
10 mg tablet dosed to 50 healthy volunteers.53
For amlodipine, study 1 included a 5 mg tablet dosed to 
24 healthy subjects,51 study 2 included a 5 mg tablet dosed to 28 
healthy volunteers (35.48±9.52 years old),54 study 3 included 
a 10 mg tablet dosed to 24 healthy volunteers (21–29 years 
old),55 and study 4 included a 10 mg tablet dosed to 35 subjects 
(18–46 years old).56 In both cases, studies 1 and 2 were used 
to develop and optimize the compound file before validating 
with two further clinical studies (studies 3 and 4).
Raw data from published human trial plasma concentra-
tion profiles were extracted using WebPlotDigitizer 3.1057 
and, where necessary, parameter estimation was conducted 
using the validation clinical datasets.
Predictions of API plasma pharmacokinetic profiles 
were simulated following the oral administration of a single 
immediate release solid dosage form of 10 mg (atorvastatin) 
and 5 mg (amlodipine) dose over a 24 h period.
statistical analysis
GraphPad PRISM software version 6.01 (San Diego, CA, 
USA) was used for data analysis. Ordinary one-way analy-
sis of variance (ANOVA) was used with Tukey’s multiple 
comparisons test to analyze data for tablet characterization. 
Unpaired two-tailed t-test was used to determine statistical dif-
ferences between data sets for pharmacokinetic parameters.
Differences between dissolution profiles of APIs in single 
dose (reference) and combination (test) were assessed using 
f
1
 and f
2
 difference and similarity factor testing using the 
equations:34
 
f
1
1 1
100= 














= =
∑ ∑
t
n
t t
t
n
t
R T R− *
 
 
f
2
2
1
0 5
50 1 1 100= + −










=
−
∑* log ( / ) ( ) *
.
n R T
t t
t
n
 
where R
t
 and T
t
 are the percent drug-dissolved value at each 
time point for the reference and test product, respectively, 
and n is the number of time points.
Results and discussion
ODT development
A 500 mg ODT formulation that was both mechanically 
robust and rapidly disintegrating was developed, which could 
be produced easily by direct compression to form 13 mm 
round, flat-faced tablets. The list of excipients was kept low 
to isolate, as best as possible, the effect of API combina-
tion. The formulation consisted of API alongside SSF as a 
water-soluble lubricant, MCC as a binder and disintegrant, 
and Pearlitol as a rapidly disintegrating diluent. Compaction 
forces were applied at a range of 1–2 T, and the effect on 
ODT properties is shown in Table 2. Hardness values were 
Table 1 input parameter values and predicted PBPK values for 
simulation of pharmacokinetics of amlodipine and atorvastatin
Parameters Amlodipine Atorvastatin
Type Diprotic base Monoprotic acid
MW 408.88 588.2
logP 3.4374 5.7
pKa 9.4, 1.9074 4.46
fu 0.0775 0.051
Vss (l/kg)
a Predicted PBPK/Pe Predicted PBPK/Pe
B:P ratio 1 0.61
clpo (l/min) 24.8 949
clint3a4
b – 8.28
Peff (cm/s) Pe Pe
JmaxP-gp (pmol/cm
2/min) – 15166
KmP-gp (μM) – 11566
raFP-gp – Pe
Notes: aVss was determined from calculation of tissue partitions coefficients within 
simcyp or parameter estimated. bin vitro intrinsic metabolic clearance (clint) was 
calculated using simcyp retrograde calculator from in vivo oral clearance and 
assuming fa=1, fg=0.2476 with cYP3a4 being the predominant metabolic pathway.77
Abbreviations: MW, molecular weight; fu, plasma unbound fraction; Vss, steady-
state volume of distribution; B:P ratio, blood-to-plasma ratio; Peff, human effective 
permeability; PBPK, physiologically based pharmacokinetic; Pe, parameter estimation; 
raF, relative activity factor; clpo, oral clearance.
Table 2 ODTs consisting of ssF (0.5% w/w) and Pearlitol Flash as 
a diluent
Compaction  
force (T)
Hardness (N) Disintegration  
time (s)
Friability (%)
1 51.40±0.26 19.33±1.53 –
1.2 68.27±5.56 20.67±4.16 –
1.4 78.23±2.96 18.33±2.52 3.97
1.6 99.37±5.28 21.33±0.58 2.46
1.8 99.83±13.67 19.67±1.15 2.29
2 100.17±7.97 20.33±0.58 1.97
Notes: The effect of altering compaction force on tablet properties is shown. Data 
presented as mean ± standard deviation.
Abbreviations: ODTs, orally disintegrating tablets; ssF, sodium stearyl fumarate.
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acceptable from a compaction force of 1.2 T and above. 
Friability values at all compaction forces were high (1%), 
with tablets compressed at and below 1.2 T not withstand-
ing friability testing. Disintegration times at all compaction 
forces were within 30 s, as advised by the FDA for ODTs58 
with no significant effect (P0.05) on disintegration with 
changes in compaction force.
Different concentrations of SSF or Mg stearate (MS) 
as lubricant were assessed for their effect on ODT proper-
ties (Table 3). No significant difference in tablet hardness 
was demonstrated when SSF concentration was altered. 
SSF ODT’s displayed greater hardness values than MS, 
with the exception of SSF at 1% w/w that was not deemed 
significant. Increasing SSF to 1.5% w/w ensured improved 
lubricant ability while maintaining high hardness and a low 
disintegration time. Inclusion of MS at 1% w/w slowed 
disintegration when compared to all other ODTs, above the 
30 s requirement (P0.01).
To combat high friability (1%), MCC was included 
as a binder.59 Addition of MCC up to 15% w/w (Table 4) 
improved hardness (P0.01) compared to other concentra-
tions while lowering friability and maintaining rapid disinte-
gration, aided by MCC’s ability to promote water penetration 
through capillary action due to its high intraparticulate 
porosity.60,61 Raising compaction force to 2.2 T lowered 
friability 1% (0.74%), maintained a low disintegration 
time of 22.67±2.52 s, and raised hardness to 137.63±2.91 
N (data not shown).
The successful formulation was implemented for 
amlodipine and atorvastatin single dose and FDC ODTs. 
Formulation compositions for all amlodipine and atorvastatin 
ODTs are shown in Table 5 and characterization in Table 6.
hPlc protocol validation
Linearity test solutions were prepared from stocks at six 
concentrations ranging from 25 to 0.8 μg/mL. Validation 
of protocols by intraday studies for amlodipine, atorvasta-
tin, and amlodipine/atorvastatin combination (Tables 7–9) 
shows the methods to be accurate and precise. Method 
accuracy is demonstrated by multilevel recovery, ranging 
from 25 to 1.5625 μg/mL. Accurate recovery was exhibited 
in all instances, ranging from 98.58% to 102.46%. Relative 
standard deviation (RSD) values representing intraday preci-
sion for amlodipine, atorvastatin, and amlodipine/atorvastatin 
ranged from 1.05% to 7.36%. Instrument precision, tested for 
by six consecutive injections of the same sample (25 μg/mL), 
was high, with RSD values ranging from 0.01% to 0.04%. 
LOQ and LOD values for amlodipine and atorvastatin alone 
were below 0.6 and 0.2 μg/mL, respectively. LOQ and LOD 
values for amlodipine/atorvastatin combination were lower 
still, falling below 0.2 and 0.1 μg/mL, correspondingly.
Dissolution
Dissolution of API from formulations f
1
–f
3
 was tested in biore-
levant media (Figures 1–4). Amlodipine dissolution from f
1
 
Table 3 ODTs containing either Ms or ssF as a lubricant
Lubricant Hardness  
(N)
Disintegration  
time (s)
Friability 
(%)
ssF 0.5% w/w 100.17±7.97 20.33±0.58 1.97
ssF 1% w/w 96.27±6.87 18.67±1.15 1.62
ssF 1.5% w/w 101.03±2.35 21.67±0.58 1.71
Ms 0.5% w/w 82.07±7.72 25.33±2.52 1.61
Ms 1% w/w 61.90±2.55 43.67±9.71 2.83
Notes: The effect of changing lubricant and lubricant concentration on ODT 
properties is shown. Data presented as mean ± standard deviation.
Abbreviations: ODTs, orally disintegrating tablets; Ms, Mg stearate; ssF, sodium 
stearyl fumarate.
Table 4 inclusion of Mcc as a binder in ODTs comprising ssF 
(1.5% w/w) and Pearlitol as a diluent
MCC Hardness  
(N)
Disintegration  
Time (s)
Friability 
(%)
5% Mcc w/w 102.03±1.62 19.33±1.15 1.67
10% Mcc w/w 106.00±3.68 20.67±1.15 1.48
15% Mcc w/w 119.50±3.90 20.33±1.15 1.04
Notes: Mcc concentrations are in % w/w. Data presented as mean ± standard 
deviation.
Abbreviations: Mcc, micro-crystalline cellulose; ODTs, orally disintegrating 
tablets; ssF, sodium stearyl fumarate.
Table 5 ODT formulations for individual dose and FDc ODTs
API/Excipient Amlodipine  
(1%)
Atorvastatin 
 (2%)
Amlodipine + 
Atorvastatin  
(1%+2%)
f1 f2 f3
amlodipine besylate 6.95 6.95
atorvastatin calcium 10.85 10.85
Pearlitol Flash 410.55 406.65 399.7
ssF (1.5%) 7.5 7.5 7.5
Mcc (15%) 75 75 75
Notes: Values for aPis and excipients are given in % w/w for 500 mg tablets. all 
formulations underwent compaction at 2.2 T with a 6 s dwell time.
Abbreviations: ODT, orally disintegrating tablet; FDC, fixed-dose combination; 
ssF, sodium stearyl fumarate; Mcc, micro-crystalline cellulose; aPis, active 
pharmaceutical ingredients.
Table 6 individual and FDc ODT properties
f Hardness  
(N)
Porosity Disintegration  
time (s)
Friability 
(%)
f1 108.00±8.35 0.23±0.15 25.33±3.21 0.71
f2 114.40±4.10 0.25±0.00 24.00±3.00 1.02
f3 117.77±8.97 0.24±0.02 21.67±1.53 0.73
Notes: all formulations underwent compaction at 2.2 T with a 6 s dwell time. Data 
presented as mean ± standard deviation.
Abbreviations: FDC, fixed-dose combination; ODT, orally disintegrating tablet.
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Table 7 hPlc method validation for detection of amlodipine
Actual conc of  
amlodipine (µg/mL)
Calculated conc of  
amlodipine (µg/mL)
RSD  
(%)
Recovery  
(%)
25 25.02±1.30 5.19 100.10±5.20
12.5 12.49±0.57 4.59 99.95±4.58
6.25 6.16±0.29 4.69 98.58±4.62
3.125 3.11±0.13 4.13 99.54±4.12
1.5625 1.59±0.06 3.68 101.83±3.75
instrument precision (% rsD) =0.02
Mean % recovery =100.00±1.18
rsD % recovery =0.01
lOD =0.17 μg/ml
lOQ =0.57 μg/ml
Correlation coefficient =0.99997
Notes: Data for linearity (correlation coefficient), instrument precision, accuracy 
(recovery), precision (% rsD), lOD, and lOQ are displayed. Data presented as 
mean ± standard deviation.
Abbreviations: hPlc, high performance liquid chromatography; rsD, relative 
standard deviation; LOD, limit of detection; LOQ, limit of quantification.
Table 8 hPlc method validation for detection of atorvastatin
Actual conc of  
atorvastatin (µg/mL)
Calculated conc of  
atorvastatin (µg/mL)
RSD  
(%)
Recovery  
(%)
25 25.05±1.44 5.76 100.19±5.77
12.5 12.42±0.66 5.34 99.34±5.31
6.25 6.23±0.38 6.08 99.72±6.07
3.125 3.08±0.23 7.36 98.42±7.24
1.5625 1.60±0.10 6.25 102.46±6.40
instrument precision (% rsD) =0.04
Mean % recovery =100.02±1.51
rsD % recovery =0.02
lOD =0.12 μg/ml
lOQ =0.40 μg/ml
Correlation coefficient =0.99996
Notes: Data for linearity (correlation coefficient), instrument precision, accuracy 
(recovery), precision (% rsD), lOD, and lOQ are displayed. Data presented as 
mean ± standard deviation.
Abbreviations: hPlc, high performance liquid chromatography; rsD, relative 
standard deviation; LOD, limit of detection; LOQ, limit of quantification.
and f
3
 in FaSSIF was rapid, with 50% dissolution within 5 
min. Near-complete dissolution (94.9%) and complete dis-
solution at (101.2%) were observed in f
1
 and f
3
, respectively. 
Amlodipine dissolution from f
1
 and f
3
 in FeSSIF peaked at 
87.9% and 79.9%, respectively. Difference and similarity 
testing comparing dissolution profiles of amlodipine from 
single and combination formulations are shown in Table 10. 
Difference and similarity testing were used as a tool to com-
pare dissolution profiles in order to predict bioequivalence. 
In fasted-state media, dissolution of amlodipine from both 
single and FDC exceeded 85% within 15 min, while f
1
 and 
f
2
 testing showed no difference between dissolution profiles. 
Dissolution in FeSSIF did not exceed 85% within 15 min 
from either single or FDC, with dissolution profiles shown 
to be different based on f
1
 and f
2
 factors.
Table 9 hPlc validation for simultaneous detection of amlodipine 
and atorvastatin
Actual conc  
(µg/mL)
Calculated conc  
(µg/mL)
RSD  
(%)
Recovery  
(%)
amlodipine
25 25.04±1.16 4.65 100.15±4.65
12.5 12.43±0.64 5.10 99.46±5.10
6.25 6.22±0.35 5.64 99.56±5.64
3.125 3.12±0.18 5.85 99.89±5.85
1.5625 1.58±0.09 6.06 100.96±6.06
instrument precision (% rsD) =0.03
Mean % recovery =100.01±0.60
rsD % recovery =0.01
lOD =0.04 μg/ml
lOQ =0.13 μg/ml
Correlation coefficient =0.99998
atorvastatin
25 25.01±0.26 1.05 100.03±1.05
12.5 12.50±0.16 1.28 99.97±1.28
6.25 6.23±0.14 2.17 99.72±2.17
3.125 3.11±0.08 2.42 99.64±2.42
1.5625 1.56±0.04 2.68 100.03±2.68
instrument precision (% rsD) =0.02
Mean % recovery =99.88±0.18
rsD % recovery =0.00
lOD =0.05 μg/ml
lOQ =0.17 μg/ml
Correlation coefficient =1
Notes: Data for linearity (correlation coefficient), instrument precision, accuracy 
(recovery), precision (% rsD), lOD, and lOQ are displayed. Data presented as 
mean ± standard deviation.
Abbreviations: hPlc, high performance liquid chromatography; rsD, relative 
standard deviation; LOD, limit of detection; LOQ, limit of quantification.
Figure 1 Amlodipine (5 mg) dissolution profiles of single and FDC formulations 
in fasted-state biorelevant media (900 ml, 37°c) from 500 mg ODTs. Dissolution 
performed using UsP 2 paddle apparatus (mean ± sD, n=3).
Abbreviations: FDC, fixed-dose combination; ODTs, orally disintegrating tablets; 
SD, standard deviation; FaSSIF, fasted-state simulated intestinal fluid; USP, United 
states Pharmacopeia. 
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Atorvastatin dissolution in FaSSIF was initially rapid, 
although peaking at 80.0% and 89.3% for single and 
FDC, respectively. Dissolution profiles in FeSSIF were 
similar to FaSSIF, with dissolution peaking at 76.9% from 
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single and 86.2% from combination formulations. Greater 
atorvastatin dissolution from FDCs was not recognized by 
f
1
 and f
2
 testing (Table 10), with no difference observed 
between dissolution profiles for single and combination 
formulations.
Based on difference and similarity testing, only amlo-
dipine in FeSSIF failed to show similar bioequivalence, 
although 85% dissolution was only observed once. This 
would suggest that a FDC ODT would likely display similar 
performance in vivo to a single dose, although based upon 
current guidelines, this is not assumed for BCS class II 
compounds. Furthermore, through development of this 
simple formulation to consistently deliver greater than 85% 
dissolution (for class I amlodipine), it may be possible to 
achieve biowaiver status.
Permeability studies
TEER values for Caco-2 cells over 21 days are shown in 
Figure 5, with cell resistance plateauing from day 18 to 
1,351.1±88.6 Ω⋅cm2 at day 21. Amlodipine and atorvastatin 
transport across Caco-2 monolayers alone and in combina-
tion was measured in both A–B and B–A directions. Drug 
transport from A to B is shown for amlodipine (Figure 6), 
atorvastatin (Figure 7), and amlodipine and atorvastatin 
combination (Figures 8 and 9). The gradient of the linear 
portion of the curve was used to calculate P
app
 values, sum-
marized in Table 11.
Figure 2 Amlodipine (5 mg) dissolution profiles of single and FDC formulations 
in fed-state biorelevant media (900 ml, 37°c) from 500 mg ODTs. Dissolution 
performed using UsP 2 paddle apparatus (mean ± sD, n=3).
Abbreviations: FDC, fixed-dose combination; ODTs, orally disintegrating tablets; 
SD, standard deviation; FeSSIF, fed-state simulated intestinal fluid.
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Figure 3 Atorvastatin (10 mg) dissolution profiles of single and FDC formulations 
in fasted-state biorelevant media (900 ml, 37°c) from 500 mg ODTs. Dissolution 
performed using UsP 2 paddle apparatus (mean ± sD, n=3).
Abbreviations: FDC, fixed-dose combination; ODTs, orally disintegrating tablets; 
SD, standard deviation; FaSSIF, fasted-state simulated intestinal fluid.
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Figure 4 Atorvastatin (10 mg) dissolution profiles of single and FDC formulations 
in fed-state biorelevant media (900 ml, 37°c) from 500 mg ODTs. Dissolution 
performed using UsP 2 paddle apparatus (mean ± sD, n=3).
Abbreviations: FDC, fixed-dose combination; ODTs, orally disintegrating tablets; 
SD, standard deviation; FeSSIF, fed-state simulated intestinal fluid.
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Table 10 Comparison of dissolution profiles for each compound 
from single and FDc formulations in FassiF and FessiF media, by 
difference factor f1 and similarity factor f2 testing
Compounds 85% dissolution  
15 min
f1 f2 Results
amlodipine
FassiF Yes 5.08 70.80 Pass
FessiF no 15.92 45.40 Fail
atorvastatin
FassiF no 14.16 53.81 Pass
FessiF no 13.24 54.59 Pass
Notes: Dissolution profiles are considered similar if the f1 value is below 15, and 
the f2 value is above 50.
Abbreviations: FDC, fixed-dose combination; FaSSIF, fasted-state simulated 
intestinal fluid; FeSSIF, fed-state simulated intestinal fluid.
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Figure 5 Teer values for caco-2 monolayers grown on 12 mm Transwell inserts 
from days 0 to 21 post-seeding. cells were seeded at a density of 8×104 cells/cm2 
and maintained in DMeM at 37°c and 5% cO2 (mean ± sD, n=6).
Abbreviations: Teer, transepithelial electrical resistance; DMeM, Dulbecco’s 
Modified Eagle’s Medium; SD, standard deviation.
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Figure 6 cumulative mass transfer of amlodipine alone (20 μg/ml) across caco-2 
monolayers (ph 7.4) simulating f1. Papp values were calculated using the gradient of 
the linear portion of the curve (mean ± sD, n=3).
Abbreviation: sD, standard deviation.
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Figure 7 cumulative mass transfer of atorvastatin alone (40 μg/ml) across caco-2 
monolayers (ph 7.4) simulating f2. Papp values were calculated using the gradient of 
the linear portion of the curve (mean ± sD, n=3).
Abbreviation: sD, standard deviation.
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Figure 8 cumulative mass transfer of amlodipine (20 μg/ml) while in combination 
with atorvastatin across caco-2 monolayers (ph 7.4) simulating f3. Papp values were 
calculated using the gradient of the linear portion of the curve (mean ± sD, n=3).
Abbreviation: sD, standard deviation.
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not significant (P0.05) but was significant in the B–A 
direction (P0.001), with the efflux ratio again maintained 
at a similar level. 
clinical trials simulation
The initial simulation of the kinetics of amlodipine and 
atorvastatin (derived from data presented in Table 1) was 
used to optimize the absorption P
eff
 and V
ss
 from clinical 
data sets 1 and 2 for each API. Optimized P
eff
 and V
ss
 were 
estimated as 1.35×10−4 cm/s and 6.12×10−4 cm/s for amlo-
dipine and 13.78 and 4.78 l/kg for atorvastatin, respectively. 
Furthermore, a RAF
P-gp
 of 8.7 was estimated to account for 
atorvastatin efflux (P-glycoprotein)63,66 contribution within 
the small intestine.
Subsequent validation of amlodipine and atorvastatin 
using validation data sets 3 and 4 for each API was successful 
P
app
 values for amlodipine closely mimic those observed 
by Rausl et al62 from both A–B and B–A. Atorvastatin P
app
 
values and efflux ratios are similar to those reported by 
Wu et al.63 An efflux ratio of 1.14 for amlodipine indicates 
passive diffusion of the compound across Caco-2 monolay-
ers, whereas an efflux ratio of 5.02 for atorvastatin suggests 
active efflux of the API in the B–A direction. Atorvastatin 
efflux, mediated primarily by P-glycoprotein, has been 
described previously in the Caco-2 model63,64 and other 
cell lines.65
When combined with atorvastatin, P
app
 values for 
amlodipine decreased significantly from A–B (P0.001) 
and B–A (P0.05), although the efflux ratio remained 
largely unchanged at 0.96. A decrease in atorvastatin P
app
 
value when in combination with amlodipine from A–B was 
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and generally centered around the mean simulated profiles 
and was within the 5th and 95th percentiles of the simulated 
profiles (Figures 10 and 11).
Simulations to predict the in vivo performance of ODTs 
in healthy volunteers were used to compare the bioavailabil-
ity between single and FDC formulations under fasted and 
fed conditions using dissolution data determined in section 
“Dissolution”. For amlodipine, the formulation state (single 
or combined) or dosing state (fasted or fed) had no statistically 
significant impact on pharmacokinetics (Figure 12A and B). 
Amlodipine plasma concentrations reached a geometric mean 
C
max
 of 2.4–2.93 ng/mL in all conditions, yielding a median 
AUC in the range 53–60 ng/mL⋅h (Table 12).
Fed-state subjects exhibited a longer median t
max
 from 
7.12 to 8.12 h in single dose and 7.45 to 8.46 h in combination 
dose profiles (Table 12). This increased t
max
 in fed subjects 
is likely a result of delayed gastric emptying and subsequent 
release of drug into the duodenum67 and has been reported 
previously for amlodipine.68
Regarding small intestine, predicted mean fraction dose 
absorbed (fa) for amlodipine correlated with dissolution 
profiles, showing significantly different (P0.0001) values 
between single and combination formulations, 0.92±0.05 
Table 11 Papp vales for amlodipine and atorvastatin alone and in 
combination in a–B and B–a directions across caco-2 monolayers 
at ph 7.4 in both compartments (n=3)
Compounds Papp (10
−6 cm s−1) Efflux ratio
A–B B–A
amlodipine 8.34±0.32 9.51±1.70 1.14
atorvastatin 2.03±0.96 10.18±0.71 5.02
amlodipine combination 5.40±0.48 5.18±0.29 0.96
atorvastatin combination 0.87±0.18 4.59±0.44 5.29
Note: Data presented as mean ± standard deviation.
Abbreviations: a–B, apical to basolateral; B–a, basolateral to apical.
Figure 11 Simulated mean plasma profile after a 10 mg oral dose of amlodipine 
(solid black line). The corresponding observed data points are shown by red (set 3) 
or green (set 4) open circles. The gray lines represent the 5th and 95th percentiles 
for the predicted values. all simulations were performed using the minimal 
PBPK model.
Abbreviation: PBPK, physiologically based pharmacokinetic.
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Figure 9 cumulative mass transfer of atorvastatin (40 μg/ml) while in combination 
with amlodipine across caco-2 monolayers (ph 7.4) simulating f3. Papp values were 
calculated using the gradient of the linear portion of the curve (mean ± sD, n=3).
Abbreviation: sD, standard deviation.
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Figure 10 Simulated mean plasma profile after a (A) 80 mg and (B) 10 mg oral dose 
of atorvastatin (solid black line). The corresponding observed data points are shown 
by red open circles. The gray lines represent the 5th and 95th percentiles for the 
predicted values. all simulations were performed using the minimal PBPK model.
Abbreviation: PBPK, physiologically based pharmacokinetic.
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and 0.95±0.04 (fasted) and 0.91±0.04 and 0.85±0.05 (fed), 
respectively.
Atorvastatin plasma profiles similarly showed no statisti-
cally significant difference (P0.05) in pharmacokinetic 
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Figure 12 Simulated mean plasma profile after a 5 mg oral dose of amlodipine (A and B) and 10 mg oral dose of atorvastatin (C and D) under fasted and fed conditions. 
Single API formulations are indicated in black and fixed-dose combination in red. Solid lines represent trial mean, and dashed lines represent the 5th and 95th percentiles for 
the predicted values. all simulations were performed using the minimal PBPK model.
Abbreviations: aPi, active pharmaceutical ingredient; PBPK, physiologically based pharmacokinetic.
(0.91±0.07). However, under fed conditions, fa was lower 
(P0.0001) for single compared to combination formula-
tions, at 0.81±0.11 and 0.91±0.09, respectively. It may 
be prudent to assume that the enhanced AUC and C
max
 for 
atorvastatin may be due to a positive food effect, given its 
BCS class II status and, therefore, lipophilic nature.69,70 
However, the impact of fasted/fed status on the fa identified 
that the absorption across the gut lumen is delayed for both 
single and combination formulations (Figure 13A). As the 
cumulative fa is a reflection of events along the entire small-
intestine lumen, the impact of food may delay the absorption 
parameters between single and combination doses in fasted 
subjects (Figure 12C). Atorvastatin plasma concentration 
increased rapidly after dosing, with a median t
max
 of 2.25 h 
in fasted and 2.56 h in fed states (Figure 12D) with a similar 
geometric mean C
max
 of 1.6–1.7 ng/mL and similar AUC 
(~16–17 ng/mL⋅h) (Table 13) for fasted states. However, under 
fed conditions there was a significant (P0.05) increase in C
max
 
for both single (2.66 ng/mL) and combination (2.96 ng/mL) 
doses, with an associated increase in the AUC (P0.0001).
Identical mean fa between single and combination 
formulations was seen for atorvastatin under fasted state 
Table 12 summary of pharmacokinetic parameters for amlodipine (5 mg) under fasted and fed conditions
Parameters Amlodipine fasted Amlodipine fed
Single Combined Single Combined
aUc (ng/ml⋅h) 53.42 (32.12–75.69) 55.12 (30.12–74.11) 60.11 (42.75–81.94) 55.36 (35.69–78.91)
cmax (ng/ml) 2.45 (1.15) 2.57 (1.23) 2.87 (1.67) 2.89 (1.17)
tmax (h) 7.12 (5.92–8.21) 7.45 (5.21–9.72) 8.12 (6.96–9.54) 8.46 (7.95–9.87)
Note: geometric mean (sD) reported for cmax and median (range) for aUc and tmax.
Abbreviation: sD, standard deviation.
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of atorvastatin into the intestinal enterocytes. However, 
when considering the mass of dosed atorvastatin within the 
stomach (10 mg) (Figure 13B), significantly greater quanti-
ties of atorvastatin remain undissolved under fed conditions 
for a longer period of time.
When considered in the context of dissolution and taking 
the duodenum as an exemplar, the estimated dissolution rates 
within the duodenum under fasted states are significantly 
faster than that under fed state, which results in a significantly 
larger duodenal luminal C
max
 (17,972 ng/mL) compared to 
the fed state (5,002 ng/mL) (Figure 13C, upper panels). 
This suggests that the differences between fasted and fed 
plasma concentrations are a result of changes in the dissolu-
tion process of the solid dosage form, otherwise uncaptured 
when considering the f
1
 and f
2
 tests, due to the dynamic and 
mechanistic nature of the ADAM-PBPK model.
As a result of this reduced dissolution under fed states, the 
absorption rate of atorvastatin in the duodenum is higher under 
fasted states with a maximal rate of 3.05 mg/h compared to 
1.77 mg/h under fed states, both at 0.28 h (Figure 13C, lower 
left panel). A consequence of this is a lower overall atorvastatin 
concentration within the enterocytes and potentially reduced 
gut metabolic clearance ab orally (Figure 13C, lower right 
panel). While the fa is relatively invariable ab orally under 
fasted or fed conditions (Figure 14A), simulations confirmed 
a noticeable decrease in the fraction of drug metabolized 
within the enterocytes under all fed conditions (Figure 14B). 
Atorvastatin possesses a low oral bioavailability (F10%) and 
this is primarily a function of its high first-pass metabolism. 
Under fed conditions, this decrease in regional ab oral fraction 
of dose metabolized would result in an increased overall oral 
bioavailability (F
oral 
= f
a 
× f
g 
× f
h
) and is, therefore, the primary 
Table 13 summary of pharmacokinetic parameters for atorvastatin (10 mg) under fasted and fed conditions
Parameters Atorvastatin fasted Atorvastatin fed
Single Combined Single Combined
aUc (ng/ml⋅h) 16.24 (2.78–64.45) 17.15 (3.04–62.99) 25.77 (5.47–75.17) 29.46 (6.73–87.72)
cmax (ng/ml) 1.61 (1.27) 1.72 (1.31) 2.66 (1.80) 2.96 (1.97)
tmax (h) 2.25 (1.51–7.86) 2.28 (1.45–5.31) 2.56 (1.45–5.25) 2.71 (1.45–5.72)
Note: geometric mean (sD) reported for cmax and median (range) for aUc and tmax.
Abbreviation: sD, standard deviation.
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Figure 13 (Continued)
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Figure 14 ab oral regional distribution of (A) median fraction dose absorbed and (B) median fraction dose metabolized for atorvastatin.
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Figure 13 (A) Mean cumulative fraction dose absorbed; (B) mean solid drug mass in the stomach (left panel) and mean dissolved stomach drug concentration (right panel); 
(C) duodenal dissolution rate (upper left panel), duodenal luminal concentration (upper right panel), duodenal absorption rate (lower left panel), and duodenal enterocyte 
concentration (lower right panel). Black solid line represents fasted (single/combined), red solid line represents fed (single), and red dashed line represents fed (combined) 
formulations.
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cause of the increased C
max
 observed under fed conditions for 
both single and combined formulations (Figure 12D).
When considering the physical process of drug absorp-
tion, it is important to conceptualize the small intestine and 
associated distribution of metabolic enzymes ab orally. 
With this in mind, CYP3A4 expression would be greatest 
duodenally and decrease longitudinally ab orally.71,72 As a 
result of this, the delayed absorption of drug across the gut 
wall (as a result of reduced dissolution) under fed states 
would result in a longer residency of solid (undissolved) 
drug in the proximal small intestine lumen, which would be 
susceptible to transit along the gut lumen until dissolution 
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was complete, resulting in absorption of atorvastatin 
more distally.
Atorvastatin is a BCS class II compound where solubility/
dissolution is the rate limiting step for absorption, coupled 
with often high metabolism. The oral bioavailability of 
atorvastatin is relatively low, indicating significant metabolic 
clearance.73 Fed state often results in slower gastric emptying 
and the presence of food alters luminal composition through 
an increase in bile salts. Indeed, post-prandial changes can 
often contribute to an increased bioavailability of many 
class II compounds. A review by Gu et al69 compared food 
effects on 92 sets of clinical data and demonstrated that 71% 
of BCS class II compounds resulted in an enhancement of 
bioavailability following meals.
Although dissolution studies in FaSSIF and FeSSIF 
are useful, the mechanistic nature of the ADAM model, 
coupled with a detailed ab oral consideration of geometric, 
physiological and biochemical variations, allows a greater 
understanding of the role of small intestine physiology on the 
process of oral drug absorption – an understanding that would 
otherwise not be captured by in vitro dissolution studies or 
subsequent statistical analysis (ie, f
1
 and f
2
 testing). Data for 
dissolution, permeability and simulated clinical trials can be 
accessed online.
Conclusion
An ODT formulation was developed and characterized, 
demonstrating acceptable performance for hardness, fri-
ability, and disintegration time and was subsequently used 
for formulation of low-dose ODTs for amlodipine and 
atorvastatin, alone and in FDC. Clinical trial simulations 
using an ADAM-PBPK model were able to predict the 
in vivo pharmacokinetics of amlodipine and atorvastatin for 
comparison of the performance of FDCs against single-dose 
formulations. In vitro dissolution data were incorporated to 
more accurately model the performance of the developed 
formulation and P
app
 values to model intestinal absorption.
Dissolution profiles showed no differences based on 
f
1
 and f
2
 testing between FDC and single-dose formulations, 
with the exception of amlodipine in FeSSIF. All FDC formu-
lations were shown to be bioequivalent based on clinical trial 
simulations in fasted and fed subjects (AUC, C
max
, and t
max
), 
despite the failure of amlodipine in FeSSIF based on f
1
 and f
2
, 
adding incentive for the use of in silico simulation. Further-
more, the demonstration of bioequivalence through f
1
 and f
2
 
and PBPK simulation for atorvastatin, a class II compound, 
adds weight to the argument for the applicability of class II 
inclusion in biowaiver applications, ideally in combination with 
PBPK modeling. Atorvastatin enjoyed a greater C
max
 and AUC 
in the fed state, due to an extended transit along the gut lumen 
as a result of poor dissolution. The attenuating expression of 
CYP3A4 distally along the gut meant that less atorvastatin 
was thus metabolized in the fed state. This food effect on the 
pharmacokinetic parameters for atorvastatin was not evident 
from in vitro investigation alone, further demonstrating the 
power and applicability of mechanistic PBPK modeling.
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